The Molecule That Ate Denmark
Sometime in late 2023, the Danish central bank did something unusual: it cut interest rates while the rest of Europe was still tightening. The reason had nothing to do with inflation expectations or slack in the labor market. It had to do with a single molecule — semaglutide — and the pharmaceutical company that manufactured it in a cluster of factories scattered across the flat countryside north of Copenhagen. Novo Nordisk's exploding exports of Ozempic and Wegovy had generated such an enormous current-account surplus that the Danish krone was threatening to break its peg to the euro, and the only way to relieve the pressure was to make Danish assets less attractive to foreign capital. A drug for Type 2 diabetes, repurposed as the most culturally consequential weight-loss treatment since the invention of the treadmill, had become so lucrative that it was distorting the monetary policy of a sovereign nation.
This is not a metaphor. Novo Nordisk's market capitalization — which peaked above $570 billion in 2024, briefly making it Europe's most valuable company, larger than LVMH, larger than the entire Danish
GDP — is the financial expression of a hundred-year bet on a single therapeutic area that the rest of pharma spent decades ignoring. The company controls roughly half the global insulin market. Its GLP-1 receptor agonist franchise, anchored by semaglutide, generated sales growth that made hardened Deutsche Bank analysts resort to words like "complete game changer." In the first half of 2023 alone, Novo's obesity care revenue surged 157% at constant exchange rates to DKK 18.1 billion. Total sales hit DKK 107.7 billion, up 30%. Operating profit rose 32%.
And yet the story of Novo Nordisk is not really about the money, or even the molecule. It is about what happens when a company decides — in a villa in Hellerup, Denmark, in 1923, and then again and again across a century of compounding institutional decisions — that the right response to a chronic disease is not to diversify away from it but to go deeper, and deeper, and deeper still.
By the Numbers
The Novo Nordisk Empire
DKK 232.3BNet sales, FY2023
~50%Global insulin market share
$570B+Peak market capitalization (2024)
69,000+Employees worldwide
157%Obesity care sales growth, H1 2023 (CER)
80Offices across the globe
100+Years of continuous diabetes focus
A Love Story as Origin Myth
The founding of Novo Nordisk is one of those origin stories that feel engineered for maximum narrative resonance — except it actually happened. Marie Krogh was among Denmark's first female medical graduates. Her husband, August Krogh, was a Nobel laureate in physiology, awarded the prize in 1920 for his work on capillary regulation. Marie had diabetes. In the early 1920s, that was a death sentence — a slow wasting that no amount of dietary restriction could arrest.
In 1921, a young Canadian surgeon named Frederick Banting and his assistant Charles Best extracted insulin from a dog's pancreas at the University of Toronto. The following year, a fourteen-year-old boy named Leonard Thompson, weighing just over 29 kilos, became the first human treated with the substance. Within twenty-four hours, his blood sugar levels dropped to near-normal. The news traveled fast.
At Marie's urging — this detail matters, because it was her disease, her insistence — August traveled to Canada to seek permission to produce insulin in Denmark. He returned with the technique and convinced Hans Christian Hagedorn, a brilliant and temperamental scientist, to join the effort alongside August Kongsted from Løvens Kemiske Fabrik. In March 1923, the first Danish patients received their insulin. Nordisk Insulinlaboratorium was born.
The founding was personal before it was commercial. Marie Krogh didn't want to diversify into adjacent therapeutic areas. She wanted to not die. That urgency — the patient as founder, the disease as origin — embedded something into the institutional DNA of the enterprise that would prove extraordinarily durable. For those interested in the full texture of the Kroghs' intertwined scientific and personal lives,
August and Marie Krogh: Lives in Science remains the definitive account.
The Sibling Rivalry That Built a Century
Two years after Nordisk began producing insulin, two brothers — Harald and Thorvald Pedersen, former Nordisk employees — walked out and formed their own company: Novo Terapeutisk Laboratorium. The split was acrimonious. It was also, in retrospect, the best thing that could have happened.
For sixty-four years, Novo and Nordisk competed viciously within the same small country, in the same narrow therapeutic category, against each other. This was not the kind of genteel Scandinavian cooperation that outsiders might imagine. Both companies built their own diabetes hospitals in the 1930s — Steno Memorial Hospital (Nordisk, 1932) and Hvidøre Diabetes Sanatorium (Novo, 1938) — not primarily out of philanthropy but because treating patients directly gave them clinical intelligence that informed product development. The hospitals were strategic assets disguised as acts of care.
⚔️
The Danish Insulin Wars
Two companies, one molecule, six decades of competition
1923Nordisk Insulinlaboratorium founded by Hagedorn and the Kroghs; first Danish patients treated with insulin.
1925Harald and Thorvald Pedersen leave Nordisk, found Novo Terapeutisk Laboratorium.
1932Nordisk establishes Steno Memorial Hospital for diabetes care and clinical research.
1938Novo opens Hvidøre Diabetes Sanatorium — the competitive response.
1946Hagedorn develops NPH insulin at Nordisk; becomes the world's dominant long-acting insulin.
1985Novo launches NovoPen, the world's first insulin delivery device resembling a pen.
1989Novo and Nordisk merge to form Novo Nordisk A/S after six decades of rivalry.
The rivalry forced innovation at a pace that a monopoly never would have. In 1946, Hagedorn developed NPH (Neutral Protamine Hagedorn) insulin — named after himself, naturally — which extended the duration of insulin action and reduced the injection burden for patients. NPH soon accounted for much of the world's consumption of longer-acting insulin. Novo, not to be outdone, invested heavily in purification technology and delivery systems, eventually producing the NovoPen in 1985 — the first insulin pen, a device so intuitive that it transformed the daily experience of millions of diabetics and established a delivery-device moat that competitors would spend decades trying to replicate.
When Novo and Nordisk finally merged in 1989, the combined entity inherited something rare: two distinct cultures of relentless incremental innovation within the same disease space, now unified under a single corporate structure with a shared foundation. The merger didn't kill the competitive energy. It internalized it.
The Architecture of Patient Captivity
What Novo Nordisk understood earlier than almost any pharmaceutical company — and what the rest of the industry is only now beginning to absorb — is that chronic disease is a platform business.
A patient diagnosed with Type 2 diabetes does not make a single purchasing decision. They make thousands of decisions, extending across decades: which insulin to use, which delivery device, which monitoring regime, which physician to trust. Each decision creates switching costs. The insulin pen that a patient learns to use at age forty-five is, in most cases, the pen they will use at sixty-five. The doctor who prescribes a particular analog insulin has trained their muscle memory around dosing protocols specific to that formulation. The insurer who negotiates a formulary placement creates a default that persists for years.
Novo Nordisk built its business around maximizing the surface area of these switching costs. The NovoPen wasn't just a delivery device — it was a razor-and-blade model. Once a patient (and their physician) committed to the pen platform, they were committed to Novo's proprietary insulin cartridges. The company invested in patient education programs, diabetes management apps, and clinical support services that deepened the relationship beyond the molecule itself. And by running its own diabetes hospitals since the 1930s, Novo accumulated a dataset of real-world patient outcomes that informed product development with a fidelity that clinical trials alone could never provide.
The result, over decades, was a market position of extraordinary stickiness. Novo Nordisk controls approximately half the global insulin market — a share that has remained remarkably stable even as competitors like Eli Lilly and Sanofi have launched their own modern insulin analogs. In a commodity business (insulin is, after all, a hundred-year-old molecule), that kind of share durability is almost unheard of. It suggests something deeper than brand loyalty. It suggests structural entrenchment.
The Willingness to Stay Narrow
The most remarkable strategic decision Novo Nordisk ever made is one it made continuously, by omission, for a century: it chose not to diversify.
This requires context. The pharmaceutical industry's dominant strategic paradigm for the past fifty years has been portfolio diversification — the idea that a drug company should spread its bets across multiple therapeutic areas to hedge against patent cliffs, regulatory setbacks, and clinical failures. Pfizer makes vaccines and oncology drugs and cardiovascular treatments. Roche does diagnostics and cancer. Johnson & Johnson does everything. The logic is straightforward: no single drug lasts forever, so you build a portfolio.
Novo Nordisk looked at this logic and said no.
The company did make selective forays into adjacent areas — growth hormones starting in the 1960s, hemophilia treatments, hormone replacement therapy. In 2000, it even spun off its enzyme business as Novozymes (a decision that itself reflected an almost fanatical commitment to focus). But the core of the enterprise remained diabetes. Decade after decade, as competitors diversified, Novo Nordisk went deeper into the metabolic system.
Ask chief executives why their companies are performing so well, and they'll typically credit a brilliant strategy coupled with hard-nosed, diligent execution. But when you ask Lars Sørensen of Novo Nordisk what forces propelled him to the top... he cites something very different: luck.
Lars Rebien Sørensen — who led Novo Nordisk as CEO from 2000 to 2016, was ranked as the best-performing CEO in the world by Harvard Business Review in 2015, and now chairs the Board of Directors — is an unusual figure for a pharma executive. Trained as a forester (his MSc from Copenhagen's Royal Veterinary and Agricultural University is in forestry) before earning a BSc in International Economics from Copenhagen Business School, Sørensen brought a naturalist's patience to corporate strategy. His instinct was to think in decades, not quarters. Under his leadership, Novo Nordisk didn't chase blockbuster opportunities in oncology or immunology. It invested — methodically, repetitively, almost boringly — in making its diabetes franchise incrementally better: better insulin analogs, better delivery devices, better patient outcomes, better relationships with endocrinologists.
The "luck" Sørensen cited was the explosion of Type 2 diabetes globally — from an estimated 30 million cases in 1985 to nearly 400 million by the time he gave that interview in 2015. But calling it luck obscures the strategic conviction required to remain concentrated in a single disease area for a century while the disease itself grew into a global pandemic. Novo Nordisk didn't get lucky. It got patient. The epidemic came to it.
The GLP-1 Epiphany
The scientific story behind semaglutide — the molecule that would become Ozempic and Wegovy and transform Novo Nordisk from a quietly excellent insulin company into the most talked-about pharmaceutical enterprise on Earth — is a masterclass in the kind of discovery that only happens when a company has spent decades immersed in a single biological system.
GLP-1 — glucagon-like peptide-1 — is a hormone produced in the gut that stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. It was identified in the 1980s. Researchers quickly realized it had potential for diabetes treatment: if you could mimic or extend GLP-1's activity, you could lower blood sugar without the weight gain and hypoglycemia risks associated with traditional insulin therapy.
The problem was that natural GLP-1 has a half-life of about two minutes. The body breaks it down almost immediately. Making a therapeutically useful GLP-1 drug required engineering a molecule that could survive long enough to do its work.
Novo Nordisk's scientists — and in particular Lotte Bjerre Knudsen, who would become the company's Chief Scientific Advisor — spent years working on this problem. The company launched liraglutide (branded as Victoza) in 2010 as a once-daily GLP-1 injection for Type 2 diabetes. It was a good drug, a meaningful advance. But the team pushed further. They engineered semaglutide — a modified GLP-1 analog designed to bind to albumin in the blood, extending its half-life to roughly a week. This single pharmacological trick — weekly dosing instead of daily — changed everything.
Ozempic (semaglutide for diabetes) received FDA approval in 2017. In 2018, its first full year on the market, Novo Nordisk's total net sales were approximately DKK 111.8 billion (roughly $17.7 billion). The drug was successful. It was not yet transformative.
The transformation came from an observation that was, in hindsight, almost obvious: patients on semaglutide were losing weight. Significant weight. The appetite-suppressing effects of GLP-1 receptor agonism — reduced hunger, earlier satiety, what patients described as the "silencing" of food noise — turned out to be not a side effect but perhaps the drug's most consequential mechanism of action.
The Wegovy Inflection
In June 2021, the FDA approved Wegovy — semaglutide at a higher dose (2.4 mg weekly) — for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It was the first weight-loss drug to receive FDA approval in eight years.
What followed was unlike anything Novo Nordisk, or arguably any pharmaceutical company, had ever experienced.
Demand didn't just exceed forecasts. It obliterated them. In the last three months of 2022, U.S. healthcare providers wrote more than 9 million prescriptions for Ozempic, Wegovy, and related GLP-1 drugs. Ozempic accounted for more than 65% of those prescriptions. Social media influencers broadcast their weight-loss journeys.
Elon Musk tweeted about it. At the 2024 Academy Awards, host Jimmy Kimmel looked out at the audience and quipped about whether Ozempic was right for him. The laughter was knowing. Ozempic had become a one-word cultural shorthand, as immediately legible as Kleenex or Google.
It's clear that nobody had expected that it would be taking off this quickly. We all along knew that obesity was a serious chronic disease also when most others did not see it like that. So we knew we were onto something big.
In the first half of 2023, Wegovy sales surged 363%. Obesity care revenue leapt 157% at constant exchange rates to DKK 18.1 billion. Total company sales rose 30% to DKK 107.7 billion. Operating profit climbed 32%. Novo Nordisk's CFO, Karsten Munk Knudsen, who had been with the company for two decades, described the U.S. uptake as surpassing "anything we've ever seen before, not just by a few percent, but by severalfold."
The company was supply-constrained. Not margin-constrained, not demand-constrained, but literally unable to manufacture enough semaglutide to meet the market. Several European countries blocked exports of their GLP-1 stockpiles to the U.S. to protect domestic supply for actual diabetics. Novo reduced dosage strengths in some markets as a rationing measure. The scarcity, perversely, amplified the drug's cachet — creating an association with exclusivity and the Hollywood elite that no marketing campaign could have engineered.
At roughly $1,000 per month out-of-pocket in the U.S., the drugs were not cheap. That price point became its own cultural signal: this was a treatment for people who could afford it, which made the people who could afford it want it more. Goldman Sachs projected the global anti-obesity drug market would reach $100 billion annually by 2030. Analysts at Mizuho suggested that semaglutide alone could eventually be worth up to $300 billion in annual sales "over time."
The Foundation Structure: Governance as Moat
To understand Novo Nordisk's strategic behavior — its patience, its willingness to stay narrow, its century-long time horizon — you have to understand the thing that makes it structurally unlike almost any other major pharmaceutical company: its ownership.
Novo Nordisk is controlled by the Novo Nordisk Foundation, which holds approximately 28% of the company's shares but controls a majority of voting rights through a dual-class share structure. The Foundation, in turn, holds its stake through Novo Holdings A/S, a massive investment vehicle that also owns Novozymes and maintains a portfolio of life-science investments.
The Foundation's charter mandates that it provide "a stable basis for the commercial and research activities" of Novo Nordisk. Its assets, swollen by the company's share price appreciation, reportedly exceeded those of the Gates Foundation by 2024 — making it the world's largest philanthropic foundation. It channels billions into scientific research, healthcare infrastructure, and education, primarily in Denmark.
This structure has profound implications. A foundation-controlled company does not face the same activist-investor pressure to return capital, pursue short-term earnings beats, or diversify into trendy therapeutic areas. It can invest in twenty-year R&D programs without quarterly conference calls full of analysts asking why the money wasn't spent on share buybacks. It can maintain a "Triple Bottom Line" principle — enshrined in Novo Nordisk's Articles of Association — requiring that business decisions balance financial, social, and environmental considerations, without worrying that a hostile bidder will argue this is a misallocation of shareholder value.
The Novo Nordisk Way — the company's internal governance document, based on principles established by its founders — codifies this orientation: "When faced with difficult choices, we think long-term, understanding that our future is dependent on adding value to society by being financially, environmentally and socially responsible."
Critics might argue that foundation control insulates management from market discipline. That's true. It's also, arguably, why the company was willing to spend decades building out GLP-1 science when shorter-time-horizon competitors would have pivoted to higher-expected-value programs. The governance structure didn't just protect patience. It demanded it.
The Nokia Risk
Novo Nordisk's extraordinary success has created an equally extraordinary vulnerability — not for the company, but for its home country.
By 2024, Novo's market capitalization exceeded Denmark's entire GDP. Its income tax bill in Denmark was $2.3 billion in 2023. Its manufacturing investments and heightened production helped the Danish economy expand nearly 2% — more than four times the EU average. Without Novo's contribution, the Danish economy would have stagnated. Danish pension funds were flush from record returns on Novo shares. Mortgages were cheaper because the central bank had to suppress interest rates to manage the krone peg. Politicians considered the company's perspective before making decisions on immigration policy or infrastructure development. Educational and research priorities were influenced by the company's agenda.
Economists call this the "Nokia risk" — a reference to the Finnish telecom giant whose decline in the 2000s dragged down Finland's entire economy, wiping out jobs, gutting university research funding, and cratering the supplier ecosystem that had built up around it. Novo Nordisk's CEO at the time, Lars Fruergaard Jørgensen, acknowledged the dynamic with a characteristically Scandinavian reference: "When you have superpowers," he said, citing the Swedish children's story Pippi Longstocking, "you have super responsibility."
The cultural dimension is revealing. Denmark has janteloven — an unofficial social code discouraging flashy displays of success. When Novo rented Copenhagen's Tivoli Gardens for a private staff party in September 2023, it asked employees not to post photos on social media "for fear of repercussions." The company quietly reduced Ozempic prices in Denmark by nearly a third following months of public debate over rising medication costs. A company that dominates its country's economy must navigate its culture with a delicacy that a global giant based in New York or Basel simply doesn't face.
The Succession and the Supply Problem
In August 2025, Novo Nordisk replaced Lars Fruergaard Jørgensen as CEO with Mike Doustdar — a choice that itself reads as a strategic signal.
Doustdar's biography is the company's international ambitions made flesh. Born in Iran, raised in the United States, educated in Austria (BA in International Business, Webster University, Vienna, 1994), he joined Novo Nordisk in 1992 as an office clerk in Vienna. Over thirty-three years he rose through finance, IT, logistics, operations, and marketing across the company's emerging markets — Near East, Oceania, Southeast Asia — before being appointed executive vice president of International Operations in 2015. By 2025, his portfolio included all global commercial units excluding the USA.
The appointment of an operations-and-commercial lifer, rather than a scientist or a strategist, suggested that the board's diagnosis of the company's most pressing challenge was not innovation but execution: manufacturing enough semaglutide to satisfy a demand curve that showed no sign of bending downward, while simultaneously navigating the U.S. pricing debate, the regulatory complexity of global weight-loss drug markets, and the competitive threat from Eli Lilly's tirzepatide (Mounjaro/Zepbound).
Lilly's entry was the first truly credible competitive challenge to Novo's GLP-1 dominance. Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed weight loss results that in some trials exceeded those of semaglutide. Mounjaro received FDA approval for Type 2 diabetes in May 2022; Zepbound, its obesity-indication version, followed. Pfizer and other companies were developing their own GLP-1 programs. The market Novo Nordisk had essentially created was, inevitably, attracting entrants.
Meanwhile, compounding pharmacies exploited an FDA provision allowing reproduction of drugs on the shortage list, creating a $1 billion annual market in unvetted semaglutide knockoffs. The market for Ozempic alone was estimated at $11 billion in 2024 and projected to hit $16.5 billion by 2029. Not all of that revenue was flowing to Novo Nordisk.
The Paradox of the Patient Company
The central paradox of Novo Nordisk is this: a company whose greatest competitive advantage is patience is now operating in a market that demands speed.
For a century, Novo Nordisk's strategy was to go deeper, not wider — to invest in the slow accumulation of manufacturing expertise, clinical data, physician relationships, and patient loyalty within a single disease space. That strategy was perfectly suited to the insulin market, which rewards reliability, incremental improvement, and institutional trust over flash. Diabetes care is a marathon. Novo trained for marathons.
The GLP-1 obesity market is a sprint. Demand materialized at a pace that outstripped manufacturing capacity. Competitive entrants arrived within years, not decades. The political economy of weight-loss drugs — pricing controversies, insurance coverage battles, cultural debates about medicalization — moves at the speed of social media, not the speed of clinical trials. Novo Nordisk must now simultaneously defend its insulin franchise, scale semaglutide production globally, develop next-generation obesity treatments (oral semaglutide, higher-efficacy analogs, combination therapies), manage a CEO transition, navigate the most hostile U.S. drug-pricing environment in a generation, and preserve the institutional culture that made all of this possible in the first place.
When you have superpowers, you have super responsibility.
Whether a company that spent a century learning to be patient can learn to be fast — without losing the thing that made its patience so valuable — is the question that will define Novo Nordisk's next decade. The foundation structure provides a shock absorber. The scientific pipeline provides optionality. The brand provides pricing power. But the market capitalization prices in a future where supply catches demand, where competitors don't catch up, and where the political system doesn't radically restructure the economics of weight-loss drugs. That's a lot of assumptions.
In Hillerød, a town better known for its four-hundred-year-old castle, twenty-six miles north of Copenhagen, blue Ozempic pens and white Wegovy pens zip along factory assembly lines in a blur. At $1,000 a month per patient, with an addressable population in the hundreds of millions, each pen that rolls off the line represents a tiny claim on the most consequential pharmacological franchise of the twenty-first century — conceived in a villa in Hellerup, funded by a foundation chartered to think in centuries, and built by a company that took a hundred years to become an overnight sensation.
